Lapatinib, a dual EGFR/HER-2 tyrosine kinase inhibitor, has been found to exert significant biologic effects on the inhibition of signaling pathways to promote breast cancer cell proliferation and survival, especially in terminal, recurrent, or metastatic breast cancer patients who had experienced anthracyclines treatment (85). The gene discussed is ERBB2; the disease is breast carcinoma.